- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Covance (NYSE: CVD) hit a new 52-week high Wednesday as it is currently trading at $72.39, above its previous 52-week high of $72.10 with 3,091 shares traded as of 9:31 a.m. ET. Average volume has been 479,200 shares over the past 30 days. Covance has a market cap of $3.97 billion and is part of the health care sector and health services industry. Shares are up 24.3% year to date as of the close of trading on Tuesday. Covance Inc., a drug development services company, provides various early-stage and late-stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries primarily in the United States and Europe. The company has a P/E ratio of 42.8, above the S&P 500 P/E ratio of 17.7.